Astraea began with a recurring question from people close to us in pharma: why did clinical analysis still depend on so many manual steps and disconnected handoffs?
Joshua Wang and Sanmay Sarada brought together experience in production AI and clinical data infrastructure to build a connected biometrics workflow. The company started with oncology and rare disease, where complex analyses make every handoff consequential.
Today, Astraea brings standards, statistical programming, quality control, and review into software that sponsor teams operate in their own environment. Experts retain the decisions; automation supports the work around them.
Our work covers the steps after a protocol is established, through submission preparation. Astraea supports statistical analysis plans, electronic case report forms, standardized study datasets (SDTM), analysis datasets (ADaM), tables, listings, and figures. The scope also includes Define-XML metadata, quality control, and submission documents. These deliverables depend on one another, so our approach connects their execution and review rather than treating each as an isolated task.
Astraea is a software platform, not a contract research organization. Forward-deployed engineers install it inside the customer’s own environment, rather than asking study teams to upload clinical data to an Astraea-hosted service. Astraea does not see customer data. Sponsors retain control of their infrastructure and trial responsibilities, while qualified experts remain accountable for scientific interpretation and acceptance of the outputs.
Our story on Y Combinator